TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy

Frontiers in Immunology

卷:12

Zhiying Shao¹  Xin Wen²  Qinggong Ma²  Jinghua Jiang²  Hui Qiu²  Yan Wang²  Long Huang²  Xin Ding²  Longzhen Zhang² 

[1] Cancer Institute, Xuzhou Medical University, Xuzhou, China;

[2] Department of Radiation Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China;

关键词: TREM2;    immune checkpoint inhibitor;    immunosuppressive myeloid cell;    cancer immunotherapy;    immune microenvironment;   

DOI  :  10.3389/fimmu.2021.716710

来源: DOAJ

【 摘 要 】

To date, immune checkpoint inhibitors have been successively approved and widely used in clinical cancer treatments, however, the overall response rates are very low and almost all cancer patients eventually progressed to drug resistance, this is mainly due to the intricate tumor microenvironment and immune escape mechanisms of cancer cells. One of the main key mechanisms leading to the evasion of immune attack is the presence of the immunosuppressive microenvironment within tumors. Recently, several studies illustrated that triggering receptor expressed on myeloid cells-2 (TREM2), a transmembrane receptor of the immunoglobulin superfamily, was a crucial pathology-induced immune signaling hub, and it played a vital negative role in antitumor immunity, such as inhibiting the proliferation of T cells. Here, we reviewed the recent advances in the study of TREM2, especially focused on its regulation of tumor-related immune signaling pathways and its role as a novel target in cancer immunotherapy.

【 授权许可】

Unknown